Risk factors of proteinuria and potentially protective effect of renin-angiotensin system inhibitors in patients with renal cell carcinoma receiving axitinib.
Hiroaki IkesueKenta YamaokaAyako MatsumotoMasaki HirabatakeNobuyuki MuroiToshinari YamasakiMutsushi KawakitaTohru HashidaPublished in: Cancer chemotherapy and pharmacology (2022)
In patients with RCC receiving axitinib, pre-existing proteinuria and non-RAS inhibitor use were significantly associated with grade ≥ 2 proteinuria development. Our preliminary data should be confirmed by further studies.